Abstract
Advances in molecular and cellular biology have identified a wide variety of proteins including targeted cytokine inhibitors, immunomodulatory proteins, cytotoxic mediators, angiogenesis inhibitors, and intracellular signalling molecules that could be of great benefit in the treatment of chronic joint diseases, such as osteo- and rheumatoid arthritis. Unfortunately, protein-based drugs are difficult to administer effectively. They have a high rate of turnover, requiring frequent readministration, and exposure in non-diseased tissue can lead to serious side effects. Gene transfer technologies offer methods to enhance the efficacy of protein-based therapies, enabling the body to produce these molecules locally at elevated levels for extended periods. The proof of concept of gene therapies for arthritis has been exhaustively demonstrated in multiple laboratories and in numerous animal models. This review attempts to condense these studies and to discuss the relative benefits and limitations of the methods proposed and to discuss the challenges toward translating these technologies into clinical realities.
Keywords: Arthritis, gene therapy, adenovirus, adeno-associated virus, lentivirus, osteoarthritis, interleukin-1, tumor necrosis factor
Current Gene Therapy
Title: Perspectives on the Use of Gene Therapy for Chronic Joint Diseases
Volume: 8 Issue: 4
Author(s): Steven C. Ghivizzani, Elvire Gouze, Jean-Noel Gouze, Jesse D. Kay, Marsha L. Bush, Rachael S. Watson, Padraic P. Levings, David M. Nickerson, Patrick T. Colahan, Paul D. Robbins and Christopher H. Evans
Affiliation:
Keywords: Arthritis, gene therapy, adenovirus, adeno-associated virus, lentivirus, osteoarthritis, interleukin-1, tumor necrosis factor
Abstract: Advances in molecular and cellular biology have identified a wide variety of proteins including targeted cytokine inhibitors, immunomodulatory proteins, cytotoxic mediators, angiogenesis inhibitors, and intracellular signalling molecules that could be of great benefit in the treatment of chronic joint diseases, such as osteo- and rheumatoid arthritis. Unfortunately, protein-based drugs are difficult to administer effectively. They have a high rate of turnover, requiring frequent readministration, and exposure in non-diseased tissue can lead to serious side effects. Gene transfer technologies offer methods to enhance the efficacy of protein-based therapies, enabling the body to produce these molecules locally at elevated levels for extended periods. The proof of concept of gene therapies for arthritis has been exhaustively demonstrated in multiple laboratories and in numerous animal models. This review attempts to condense these studies and to discuss the relative benefits and limitations of the methods proposed and to discuss the challenges toward translating these technologies into clinical realities.
Export Options
About this article
Cite this article as:
Ghivizzani C. Steven, Gouze Elvire, Gouze Jean-Noel, Kay D. Jesse, Bush L. Marsha, Watson S. Rachael, Levings P. Padraic, Nickerson M. David, Colahan T. Patrick, Robbins D. Paul and Evans H. Christopher, Perspectives on the Use of Gene Therapy for Chronic Joint Diseases, Current Gene Therapy 2008; 8 (4) . https://dx.doi.org/10.2174/156652308785160638
DOI https://dx.doi.org/10.2174/156652308785160638 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rheological Characteristics of Novel Meloxicam-Loaded Complex Organogels Based on Fumed Silica and Poloxamer
Current Drug Delivery Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development of New Drugs for COPD
Current Medicinal Chemistry α-Amino-α´-Halomethylketones: Synthetic Methodologies and Pharmaceutical Applications as Serine and Cysteine Protease Inhibitors
Mini-Reviews in Medicinal Chemistry Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes
Current Pharmaceutical Design Rheumatology: A Force for Change in Monoclonal Antibodies
Current Pharmaceutical Design Biologics in Systemic Sclerosis
Current Pharmaceutical Biotechnology Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Autoimmune Hepatitis After Long-Term Methotrexate Therapy for Rheumatoid Arthritis
Current Drug Safety 3D-QSAR Analysis on Pyrrolopyridine Analogs as Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2) Inhibitors
Letters in Drug Design & Discovery Editorial: The Explosion of Biosimilars in Immune Mediated Chronic Inflammatory Diseases
Current Pharmaceutical Design Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist
Current Rheumatology Reviews Applications of Animal Models of Infectious Arthritis in Drug Discovery:A focus on Alphaviral Disease
Current Drug Targets Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Antimicrobial Agents Deriving from Indigenous Plants
Recent Patents on Food, Nutrition & Agriculture The Role of miRNAs in Cartilage Homeostasis
Current Genomics Cathepsin L Induces Proangiogenic Changes in Human Omental Microvascular Endothelial Cells via Activation of the ERK1/2 Pathway
Current Cancer Drug Targets Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews